GlassScriptPhysician profile
Samuel N Ofori
NPI 1548285703
$3,887.50
in general payments reported to CMS, 2019-2025
30 companies · $1,512 in 2025
The $1,512 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $62.50 · 2021: $193 · 2022: $439 · 2023: $498 · 2024: $1,044 · 2025: $1,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $1,863 · Food and Beverage: $1,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $1,863.04 |
| Food and Beverage | $1,190.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,197.62 | 2021-2025 | |
| Gilead Sciences, INC. | $157.47 | 2022-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $152.44 | 2022-2023 | Keytruda, Lynparza |
| Amgen INC. | $151.87 | 2019-2023 | Lumakras |
| Exelixis INC. | $140.08 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $133.38 | 2019-2025 | Opdivo |
| Pfizer INC. | $111.30 | 2022-2024 | |
| Astellas Pharma US INC | $95.61 | 2019-2025 | Padcev, Xtandi |
| Celgene Corporation | $85.83 | 2023 | Pomalyst, Reblozyl |
| Abbvie INC. | $83.61 | 2023-2025 | |
| Daiichi Sankyo INC. | $79.07 | 2022-2025 | Enhertu, Datroway |
| Janssen Biotech, INC. | $72.98 | 2019-2025 | Carvykti |
| Genentech USA, INC. | $50.93 | 2019-2023 | Lunsumio, Polivy |
| Ipsen Biopharmaceuticals, INC | $45.17 | 2019-2024 | Onivyde |
| Tempus Ai, INC | $39.09 | 2024 | Xt Cdx |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $31.57 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $25.31 | 2021 | |
| Karyopharm Therapeutics INC. | $23.82 | 2025 | Xpovio |
| Alexion Pharmaceuticals, INC. | $22.81 | 2024 | Ultomiris |
| Stemline Therapeutics INC. | $21.28 | 2025 | Orserdu |
| Sobi, INC | $21.16 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.36 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $20.29 | 2022 | |
| Lilly USA, LLC | $20.07 | 2025 | Jaypirca, Verzenio |
| Eisai INC. | $18.74 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $13.94 | 2023 | Imfinzi |
| Array Biopharma INC | $13.53 | 2022 | |
| Emd Serono, INC. | $13.04 | 2019 | |
| Dova Pharmaceuticals | $12.60 | 2019 | |
| Glaxosmithkline, LLC. | $12.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Ofori listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.